Director at Intelligent Bio Solutions (INBS) awarded 5,000 restricted shares

Rhea-AI Filing Summary

Isenberg Jason reported acquisition or exercise transactions in this Form 4 filing.

INTELLIGENT BIO SOLUTIONS INC. director Jason Isenberg reported an equity award of 5,000 shares of Common Stock. The shares were granted on March 18, 2026 under the company’s 2019 Long Term Incentive Plan at no cash cost and are his entire reported direct holding of 5,000 shares.

The 5,000 shares are restricted stock that vest after 12 months and are subject to forfeiture until they vest. All share amounts are presented on a post–1-for-10 reverse stock split basis reflecting the reverse split effected on December 15, 2025 and earlier reverse splits.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Isenberg Jason

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,000	$0.00	--

Holdings After Transaction: Common Stock — 5,000 shares (Direct)

Footnotes (1)

1. On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis. On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Isenberg Jason

(Last) (First) (Middle)

C/O INTELLIGENT BIO SOLUTIONS INC.,

135 WEST 41ST STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTELLIGENT BIO SOLUTIONS INC. [ INBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A		5,000(2)	A	$0	5,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

2. On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

	/s/ Jason Isenberg	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did INBS director Jason Isenberg report on this Form 4?

Jason Isenberg reported receiving 5,000 shares of INBS Common Stock as an equity award. The shares were granted on March 18, 2026 under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan and represent a compensation-related acquisition, not an open-market stock purchase.

How many INBS shares does Jason Isenberg hold after this reported equity award?

After the reported transaction, Jason Isenberg directly holds 5,000 shares of Intelligent Bio Solutions Inc. Common Stock. This entire position comes from the March 18, 2026 grant of restricted shares reported on the Form 4, with no additional direct holdings disclosed in this filing.

Was the INBS Form 4 transaction an open-market buy or a stock grant?

The transaction was a stock grant, not an open-market purchase. Isenberg received 5,000 restricted shares of Common Stock at a reported price of $0.0000 per share as part of the company’s 2019 Long Term Incentive Plan, indicating a compensation award rather than a market trade.

What are the vesting terms of Jason Isenberg’s 5,000 INBS restricted shares?

The 5,000 restricted shares of INBS Common Stock vest after 12 months. Until vesting, the award is subject to forfeiture, meaning Isenberg’s continued service and satisfaction of the plan’s conditions are required before the shares become fully owned and no longer at risk of being forfeited.

How did Intelligent Bio Solutions’ reverse stock split affect the Form 4 share numbers?

All share amounts in the Form 4 are shown after Intelligent Bio Solutions’ 1-for-10 reverse stock split. That reverse split occurred on December 15, 2025 and, together with prior reverse splits, reduced reported share counts and proportionally adjusted outstanding equity awards held by the reporting person.

Under which plan were Jason Isenberg’s INBS restricted shares granted?

The 5,000 restricted shares were granted under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. This plan is used by the company to provide equity-based compensation, and the reported award reflects a director-level grant subject to time-based vesting and potential forfeiture before vesting.